Clinical Trials Logo

Vulvar Diseases clinical trials

View clinical trials related to Vulvar Diseases.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06075264 Recruiting - HPV Infection Clinical Trials

Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)

ART-VIN IIB
Start date: December 6, 2023
Phase: Phase 2
Study type: Interventional

This is a phase II double-blind, placebo-controlled study of artesunate ointment for the treatment of HPV-associated vulvar HSIL (usual type vulvar intraepithelial neoplasia 2/3).

NCT ID: NCT05890092 Recruiting - Vulvar Diseases Clinical Trials

Vulvar Disease in Nigeria Observational Study

VdiN
Start date: May 3, 2023
Phase:
Study type: Observational [Patient Registry]

Vulvar disease in Nigeria A look at awareness within patients and health practitioners, self-reported and actual prevalence within communities in Nigeria

NCT ID: NCT05592626 Recruiting - Neoplasms Clinical Trials

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

START-001
Start date: January 4, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-rich.

NCT ID: NCT02858310 Recruiting - Clinical trials for Cervical Intraepithelial Neoplasia

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

Start date: January 27, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Background: Human papillomavirus (HPV) can cause cervical, throat, anal, and genital cancers. Cancers caused by HPV have a HPV protein called E7 inside of their cells. In this new therapy, researchers take a person s blood, remove certain white blood cells, and insert genes that make them to target cancer cells that have the E7 protein. The genetically changed cells, called E7 TCR cells, are then given back to the person to fight the cancer. Researchers want to see if this can help people. Objective: To determine a safe dose and efficacy of E7 TCR cells and whether these cells can help patients. Eligibility: Adults ages 18 and older with an HPV-16-associated cancer, including cervical, vulvar, vaginal, penile, anal, or oropharyngeal. Design: Participants will list all their medicines. Participants will have many screening tests, including imaging procedures, heart and lung tests, and lab tests. They will have a large catheter inserted into a vein. Participants will have leukapheresis. Blood will be removed through a needle in the arm. A machine separates the white blood cells. The rest of the blood is returned through a needle in the other arm. The cells will be changed in the lab. Participants will stay in the hospital. Over several days, they will get: Chemotherapy drugs E7 TCR cells Shots or injections to stimulate the cells Participants will be monitored in the hospital up to 12 days. They will get support medicine and have blood and lab tests. Participants will have a clinic visit about 40 days after cell infusion. They will have a physical exam, blood work, scans, and maybe x-rays. Participants will have many follow-up visits with the same procedures. At some visits, they may undergo leukapheresis. Participants will be followed for 15 years.

NCT ID: NCT00119886 Recruiting - Vulvar Vestibulitis Clinical Trials

Botox on Vulvar Vestibulitis

Start date: April 2005
Phase: Phase 4
Study type: Interventional

The study seeks to evaluate the effect of botulinum toxin on vulvar vestibulitis (VVS) after local injection with Botox, a potential treatment to relieve patients of vulvar pain, reducing the need for painkillers, and improving the sexual quality of life of the patients.